Exelixis
EXEL
#1645
Rank
NZ$16.60 B
Marketcap
$59.33
Share price
-2.49%
Change (1 day)
49.69%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): NZ$1.13 Billion

According to Exelixis's latest financial reports the company's current earnings are NZ$2.16 Billion. , an increase over its 2023 earnings that were of NZ$0.44 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 NZ$1.17 B164.69%
2023 NZ$0.44 B9.89%
2022 NZ$0.40 B-20.33%
2021 NZ$0.50 B124.82%
2020 NZ$0.22 B-67.14%
2019 NZ$0.68 B-11.94%
2018 NZ$0.77 B185.09%
2017 NZ$0.27 B-325.82%
2016 -NZ$0.13 Billion-58.12%
2015 -NZ$0.29 Billion-37.61%
2014 -NZ$0.47 Billion9.75%
2013 -NZ$0.43 Billion65.96%
2012 -NZ$0.26 Billion-291.63%
2011 NZ$0.13 B-195.59%
2010 -NZ$0.14 Billion-42.17%
2009 -NZ$0.24 Billion-18.98%
2008 -NZ$0.3 Billion-6.99%
2007 -NZ$0.32 Billion46.3%
2006 -NZ$0.22 Billion33.25%
2005 -NZ$0.17 Billion-30.92%
2004 -NZ$0.24 Billion44.29%
2003 -NZ$0.17 Billion12.86%
2002 -NZ$0.15 Billion22.79%
2001 -NZ$0.12 Billion60.14%
2000 -NZ$73.8 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
NZ$7.56 B 544.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$13.67 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$36.51 B 3,011.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$14.43 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$7.93 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$30.02 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$19.13 B 1,530.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$73.65 Million-106.28%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$50 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA